Unicus Mups20 mg

Unicus Mups is a proton pump inhibitor (PPI) used to reduce stomach acid production. Its indications are classified below by strength of evidence.

Established / FDA-approved uses

• Treatment of gastroesophageal reflux disease (GERD), including symptomatic relief of heartburn
• Healing of erosive esophagitis and maintenance of healing to prevent relapse
• Risk reduction of gastric ulcer associated with continuous NSAID use
• Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome

Uses requiring combination therapy

• Unicus Mups combined with amoxicillin and clarithromycin (triple therapy) for eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence

Guideline-supported / adjunct uses

• Adjunct therapy in patients receiving long-term NSAID or low-dose aspirin therapy who are at risk of gastrointestinal bleeding

Use of Unicus Mups for indications not listed above should only be based on a physician's advice.

Each dose of Esomeprazole Magnesium delayed-release formulation contains esomeprazole magnesium equivalent to esomeprazole free base, commonly available in strengths of 20 mg and 40 mg as delayed-release capsules, tablets, or oral suspension granules.

Unicus Mups is the magnesium salt of esomeprazole, the S-isomer of omeprazole, and belongs to the class of proton pump inhibitors (PPIs). It is formulated as a delayed-release (enteric-coated) preparation because esomeprazole is acid-labile, and is used to reduce gastric acid secretion in a range of acid-related disorders.

Unicus Mups belongs to the therapeutic class of Proton Pump Inhibitors (PPIs), a group of drugs used to reduce gastric acid secretion.

Esomeprazole Magnesium is a substituted benzimidazole that is metabolized to an active sulfenamide form within the acidic environment of gastric parietal cells. This active form binds covalently and irreversibly to the H⁺/K⁺-ATPase (proton pump) on the luminal surface of the parietal cell membrane, blocking the final step of acid production. Because binding is irreversible, acid suppression persists until new proton pump molecules are synthesized, allowing once-daily dosing despite a short plasma half-life (approximately 1-1.5 hours). Esomeprazole Magnesium is well absorbed, undergoes extensive hepatic metabolism primarily via CYP2C19 and to a lesser extent CYP3A4, and is excreted mainly in urine as inactive metabolites.

Unicus Mups delayed-release capsules or tablets should be swallowed whole with water, at least one hour before a meal, and not crushed or chewed, as this would destroy the enteric coating that protects the drug from stomach acid. For patients unable to swallow capsules, the capsule may be opened and the granules mixed with a small amount of applesauce or dispersed in water per product-specific instructions, and swallowed immediately without chewing. Oral suspension packets should be mixed with water only, not other liquids or food, and taken immediately.

Unicus Mups is associated with the following clinically significant drug interactions:

• Clopidogrel: reduces conversion of clopidogrel to its active metabolite via CYP2C19 inhibition, potentially reducing its antiplatelet effect; concomitant use should be avoided when possible.
• Rilpivirine-containing products: significantly decreases rilpivirine absorption due to increased gastric pH; concomitant use is contraindicated.
• Warfarin: may increase INR and prothrombin time, raising bleeding risk; monitoring is advised.
• Methotrexate (high-dose): may increase and prolong serum methotrexate levels, increasing toxicity risk; temporary withdrawal of Unicus Mups may be considered.
• Atazanavir and other pH-dependent antiretrovirals: absorption is reduced by increased gastric pH; concomitant use is generally not recommended.
• CYP2C19 inducers (e.g., rifampin, St. John's Wort): may substantially decrease esomeprazole plasma levels.
• CYP2C19/CYP3A4 inhibitors (e.g., voriconazole): may increase esomeprazole plasma levels.
• Digoxin and other drugs dependent on gastric pH for absorption: altered absorption is possible; monitoring may be needed.

Common side effects of Unicus Mups include headache, nausea, diarrhea, abdominal pain, constipation, flatulence, and dry mouth. These are usually mild and transient.

Less common but clinically important effects associated with long-term use include:

• Increased risk of bone fracture (hip, wrist, spine) with long-term or high-dose use
• Hypomagnesemia, sometimes severe, with prolonged use (generally beyond 3 months)
• Vitamin B12 deficiency with prolonged use
• Clostridioides difficile-associated diarrhea
• Acute interstitial nephritis and, rarely, chronic kidney disease
• Cutaneous and systemic lupus erythematosus (rare)
• Fundic gland polyps with long-term use

Patients should seek medical advice if they experience persistent diarrhea, unexplained weight loss, or signs of an allergic reaction while taking Unicus Mups.

Unicus Mups should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use. Available data have not shown a clear pattern of major birth defects, but adequate well-controlled studies remain limited.

Esomeprazole is excreted in breast milk in small amounts. Use of Unicus Mups during breastfeeding should be discussed with a physician, weighing the benefit to the mother against any potential risk to the infant.

The following precautions apply to the use of Unicus Mups:

• Symptomatic response does not exclude the presence of gastric malignancy; Unicus Mups may mask symptoms and delay diagnosis, so gastric malignancy should be considered or excluded before starting therapy, particularly in patients with alarm symptoms (weight loss, recurrent vomiting, dysphagia, GI bleeding, anemia).
• Long-term use (generally beyond one year) is associated with increased risk of bone fracture; use the lowest effective dose for the shortest duration appropriate to the condition.
• Prolonged use may cause hypomagnesemia and vitamin B12 deficiency; periodic monitoring may be considered in patients on long-term therapy or those taking other drugs that lower magnesium (e.g., diuretics).
• Increased risk of Clostridioides difficile-associated diarrhea; consider this diagnosis in patients with persistent diarrhea.
• Use caution in patients with hepatic impairment; dose adjustment may be needed in severe hepatic impairment.
• Not intended for immediate symptom relief; onset of action is not immediate.

See Contraindications and Drug Interactions for further safety information.

Reported experience with Unicus Mups overdose is limited. Symptoms, if they occur, are generally mild and may include confusion, drowsiness, blurred vision, tachycardia, nausea, sweating, and dry mouth. There is no specific antidote. In case of suspected overdose, seek immediate medical attention or contact a poison control center; treatment is supportive and symptomatic.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use: Unicus Mups is approved for short-term treatment of GERD-related erosive esophagitis in infants 1 month to less than 1 year of age (weight-based dosing) and for GERD in children 1 to 17 years of age, with dosing adjusted by age and body weight. Safety and efficacy for other indications in children have not been established.

Elderly: No overall dose adjustment is required based on age alone, though elderly patients may have higher susceptibility to fracture and hypomagnesemia risks with long-term use.

Renal impairment: No dose adjustment is generally required; limited data are available in patients with severe renal impairment.

Hepatic impairment: Dose adjustment (maximum 20 mg daily) is recommended in patients with severe hepatic impairment; no adjustment is generally needed in mild-to-moderate impairment.

Duration of Unicus Mups therapy depends on the indication: typically 4 weeks for symptomatic GERD, 4-8 weeks for healing of erosive esophagitis, up to 6 months for maintenance therapy or NSAID-associated ulcer risk reduction, 10 days for H. pylori eradication regimens, and long-term individualized therapy for hypersecretory conditions such as Zollinger-Ellison syndrome. Treatment beyond the recommended duration should only continue under physician supervision.

Proton Pump Inhibitor (PPI); Antisecretory / antiulcer agent; Substituted benzimidazole.

Esomeprazole Magnesium works by irreversibly inhibiting the H⁺/K⁺-ATPase enzyme system (the "proton pump") located on the secretory surface of gastric parietal cells. This blocks the final common pathway of gastric acid secretion, whether stimulated by histamine, gastrin, or acetylcholine, resulting in a marked and long-lasting reduction of both basal and stimulated gastric acid output.

B (legacy FDA pregnancy category)

Unicus Mups is approved for use in pediatric patients as follows:

• 1 month to less than 1 year: short-term treatment (up to 6 weeks) of erosive esophagitis due to acid-mediated GERD, using weight-based dosing as advised by a pediatrician.
• 1 to 11 years: treatment of GERD, dosed by body weight, generally for up to 8 weeks.
• 12 to 17 years: treatment of GERD, at doses similar to adult dosing (20 mg once daily), generally for 4-8 weeks.

Safety and efficacy of Unicus Mups for indications such as H. pylori eradication or hypersecretory conditions have not been established in pediatric patients, and use for these indications should only be based on a physician's judgment.